Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 5/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315298 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 | |
| Sp-420 SCHEMBL31756853 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 | |
| SCHEMBL30754443 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 | |
| SCHEMBL1315276 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 | |
| Sp-420 SCHEMBL1314906 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 | |
| SCHEMBL15923274 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 | |
| SCHEMBL1315301 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 | |
| SCHEMBL11963323 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 | |
| SCHEMBL11963439 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 | |
| SCHEMBL11963440 | 1.00 | SLC22A12 (0.37) | SLC22A12OPRK1KDM4ETDP1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725559-A2 | DOSING REGIMENS FOR TREATING METAL-MEDIATED CONDITIONS | Abfero Pharmaceuticals, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20250205275-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-06-26 | — | — | US | claimed |
| EP-4499113-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-02-05 | — | — | EP | claimed |
| WO-2023178445-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2023-09-28 | — | — | WO | claimed |
| WO-2022037594-A1 | USE OF IRON CHELATING AGENT IN PREPARATION OF DRUG FOR TREATING OR PREVENTING POLYOMAVIRUS INFECTION | 上海市公共卫生临床中心 | 2022-02-24 | — | — | WO | claimed |
| CN-114073772-A | Use of an iron chelator for the treatment or prevention of polyoma viral infections | 上海市公共卫生临床中心 | 2022-02-22 | — | — | CN | claimed |
| US-20210322301-A1 | DOSING REGIMENS FOR TREATING METAL-MEDIATED CONDITIONS | ABFERO PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | US | claimed |
| EP-3493801-A1 | DOSING REGIMENS FOR TREATING METAL-MEDIATED CONDITIONS | Abfero Pharmaceuticals, Inc. (US) | 2019-06-12 | — | — | EP | claimed |
| US-20180344644-A1 | IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF | IKARIA THERAPEUTICS LLC | 2018-12-06 | — | — | US | claimed |
| EP-3352733-A1 | IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF | Mallinckrodt LLC (US) | 2018-08-01 | — | — | EP | claimed |
| US-20180036228-A1 | DOSING REGIMENS FOR TREATING METAL-MEDIATED CONDITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2018-02-08 | — | — | US | claimed |
| WO-2018027132-A1 | DOSING REGIMENS FOR TREATING METAL-MEDIATED CONDITIONS | ABFERO PHARMACEUTICALS, INC. (US) | 2018-02-08 | — | — | WO | claimed |
| WO-2017053464-A1 | IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF | MALLINCKRODT LLC (US) | 2017-03-30 | — | — | WO | claimed |
| EP-4725559-A2 | DOSING REGIMENS FOR TREATING METAL-MEDIATED CONDITIONS | Abfero Pharmaceuticals, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250205275-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-06-26 | — | — | US | disclosed |
| EP-4499113-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-02-05 | — | — | EP | disclosed |
| US-20100137383-A1 | NOVEL SALTS AND POLYMORPHS OF DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137383-A1 | NOVEL SALTS AND POLYMORPHS OF DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010009120-A2 | NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20080214630-A1 | Oral bioavailability; minimal toxicity; low concentration in the kidneys after administration; reduce oxidative stress; (S)-4,5-Dihydro-2-[2-hydroxy-4-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid; condition responsive to chelation or sequestration of a trivalent metal | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344644-A1 | IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF | SGMS2, SGMS1, LIPA | SLC22A12 816/4885OPRK1 4409/4885KDM4E 3247/4885 |
| US-20250205275-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | SLC40A1, TFRC, FANCF | SLC22A12 801/4885OPRK1 3686/4885KDM4E 3058/4885 |
| US-20080214630-A1 | Oral bioavailability; minimal toxicity; low concentration in the kidneys after administration; reduce oxidative stress; (S)-4,5-Dihydro-2-[2-hydroxy-4-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid; condition responsive to chelation or sequestration of a trivalent metal | SLC7A1, SLC19A1, SLC10A6 | SLC22A12 35/4885OPRK1 1298/4885KDM4E 1297/4885 |
| US-20100137383-A1 | NOVEL SALTS AND POLYMORPHS OF DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | SLC39A14, SLC40A1, SLC39A11 | SLC22A12 54/4885OPRK1 1535/4885KDM4E 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.